APO Research
Talk to an analyst

APO RESEARCH · REPORT

Helicobacter Pylori Infection Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Helicobacter Pylori Infection Treatment Market Analysis and Forecast 2026-2032

5 July 2026172 pages

Choose your research edition.

Industry ResearchHelicobacter Pylori Infection Treatment Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Helicobacter Pylori Infection Treatment Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Helicobacter Pylori Infection Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Helicobacter Pylori Infection Treatment Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Helicobacter Pylori Infection Treatment Market Analysis and Forecast 2026-2032172 pages · $4,950 USD

Market perspective

The global Helicobacter Pylori Infection Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Helicobacter Pylori Infection Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Helicobacter Pylori Infection Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Helicobacter Pylori Infection Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Helicobacter Pylori Infection Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Helicobacter Pylori Infection Treatment include Cumberland Pharmaceuticals, Eisai Co., Bio-Rad Laboratories, F. Hoffmann-La Roche, Alpha Laboratories, Biohit, Phathom Pharmaceuticals, Redhill Biopharma and Takeda Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Helicobacter Pylori Infection Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Helicobacter Pylori Infection Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Helicobacter Pylori Infection Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Helicobacter Pylori Infection Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Helicobacter Pylori Infection Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Helicobacter Pylori Infection Treatment revenue, projected growth trends, production technology, application and end-user industry.

Helicobacter Pylori Infection Treatment Segment by Company

Cumberland Pharmaceuticals

Eisai Co.

Bio-Rad Laboratories

F. Hoffmann-La Roche

Alpha Laboratories

Biohit

Phathom Pharmaceuticals

Redhill Biopharma

Takeda Pharmaceuticals

AbbVie

Helicobacter Pylori Infection Treatment Segment by Type

Bismuth-quadruple Therapy

Concomitant Therapy

Levofloxacin Triple Therapy

Bismuth Therapy

High-dose Dual Therapy

Helicobacter Pylori Infection Treatment Segment by Application

Hospitals

Diagnostics Laboratories

Clinics

Helicobacter Pylori Infection Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Helicobacter Pylori Infection Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Helicobacter Pylori Infection Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Helicobacter Pylori Infection Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Helicobacter Pylori Infection Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Helicobacter Pylori Infection Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Helicobacter Pylori Infection Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Helicobacter Pylori Infection Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Bismuth-quadruple Therapy Major Player Table 3. Concomitant Therapy Major Player Table 4. Levofloxacin Triple Therapy Major Player Table 5. Bismuth Therapy Major Player Table 6. High-dose Dual Therapy Major Player Table 7. Global Helicobacter Pylori Infection Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospitals Major Player Table 9. Diagnostics Laboratories Major Player Table 10. Clinics Major Player Table 11. Helicobacter Pylori Infection Treatment Industry Trends Table 12. Helicobacter Pylori Infection Treatment Industry Drivers Table 13. Helicobacter Pylori Infection Treatment Industry Opportunities and Challenges Table 14. Helicobacter Pylori Infection Treatment Industry Restraints Table 15. Global Helicobacter Pylori Infection Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Helicobacter Pylori Infection Treatment Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Helicobacter Pylori Infection Treatment Market Share by Region (2021-2026) Table 18. Global Helicobacter Pylori Infection Treatment Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Helicobacter Pylori Infection Treatment Market Share by Region (2027-2032) Table 20. Global Helicobacter Pylori Infection Treatment Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Helicobacter Pylori Infection Treatment Revenue Market Share by Players (2021-2026) Table 22. Global Helicobacter Pylori Infection Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Helicobacter Pylori Infection Treatment Key Players Headquarters & Area Served Table 24. Global Helicobacter Pylori Infection Treatment Players, Product Type & Application Table 25. Global Helicobacter Pylori Infection Treatment Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Helicobacter Pylori Infection Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Helicobacter Pylori Infection Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Helicobacter Pylori Infection Treatment Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Helicobacter Pylori Infection Treatment Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Helicobacter Pylori Infection Treatment Revenue Market Share by Type (2021-2026) Table 32. Global Helicobacter Pylori Infection Treatment Revenue Market Share by Type (2027-2032) Table 33. Global Helicobacter Pylori Infection Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Helicobacter Pylori Infection Treatment Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Helicobacter Pylori Infection Treatment Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Helicobacter Pylori Infection Treatment Revenue Market Share by Application (2021-2026) Table 37. Global Helicobacter Pylori Infection Treatment Revenue Market Share by Application (2027-2032) Table 38. Cumberland Pharmaceuticals Company Information Table 39. Cumberland Pharmaceuticals Business Overview Table 40. Cumberland Pharmaceuticals Helicobacter Pylori Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Cumberland Pharmaceuticals Helicobacter Pylori Infection Treatment Product Portfolio Table 42. Cumberland Pharmaceuticals Recent Development Table 43. Eisai Co. Company Information Table 44. Eisai Co. Business Overview Table 45. Eisai Co. Helicobacter Pylori Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Eisai Co. Helicobacter Pylori Infection Treatment Product Portfolio Table 47. Eisai Co. Recent Development Table 48. Bio-Rad Laboratories Company Information Table 49. Bio-Rad Laboratories Business Overview Table 50. Bio-Rad Laboratories Helicobacter Pylori Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Bio-Rad Laboratories Helicobacter Pylori Infection Treatment Product Portfolio Table 52. Bio-Rad Laboratories Recent Development Table 53. F. Hoffmann-La Roche Company Information Table 54. F. Hoffmann-La Roche Business Overview Table 55. F. Hoffmann-La Roche Helicobacter Pylori Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. F. Hoffmann-La Roche Helicobacter Pylori Infection Treatment Product Portfolio Table 57. F. Hoffmann-La Roche Recent Development Table 58. Alpha Laboratories Company Information Table 59. Alpha Laboratories Business Overview Table 60. Alpha Laboratories Helicobacter Pylori Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Alpha Laboratories Helicobacter Pylori Infection Treatment Product Portfolio Table 62. Alpha Laboratories Recent Development Table 63. Biohit Company Information Table 64. Biohit Business Overview Table 65. Biohit Helicobacter Pylori Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Biohit Helicobacter Pylori Infection Treatment Product Portfolio Table 67. Biohit Recent Development Table 68. Phathom Pharmaceuticals Company Information Table 69. Phathom Pharmaceuticals Business Overview Table 70. Phathom Pharmaceuticals Helicobacter Pylori Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Phathom Pharmaceuticals Helicobacter Pylori Infection Treatment Product Portfolio Table 72. Phathom Pharmaceuticals Recent Development Table 73. Redhill Biopharma Company Information Table 74. Redhill Biopharma Business Overview Table 75. Redhill Biopharma Helicobacter Pylori Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Redhill Biopharma Helicobacter Pylori Infection Treatment Product Portfolio Table 77. Redhill Biopharma Recent Development Table 78. Takeda Pharmaceuticals Company Information Table 79. Takeda Pharmaceuticals Business Overview Table 80. Takeda Pharmaceuticals Helicobacter Pylori Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Takeda Pharmaceuticals Helicobacter Pylori Infection Treatment Product Portfolio Table 82. Takeda Pharmaceuticals Recent Development Table 83. AbbVie Company Information Table 84. AbbVie Business Overview Table 85. AbbVie Helicobacter Pylori Infection Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. AbbVie Helicobacter Pylori Infection Treatment Product Portfolio Table 87. AbbVie Recent Development Table 88. North America Helicobacter Pylori Infection Treatment Revenue by Type (2021-2026) & (US$ Million) Table 89. North America Helicobacter Pylori Infection Treatment Revenue by Type (2027-2032) & (US$ Million) Table 90. North America Helicobacter Pylori Infection Treatment Revenue by Application (2021-2026) & (US$ Million) Table 91. North America Helicobacter Pylori Infection Treatment Revenue by Application (2027-2032) & (US$ Million) Table 92. North America Helicobacter Pylori Infection Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 93. North America Helicobacter Pylori Infection Treatment Revenue by Country (2021-2026) & (US$ Million) Table 94. North America Helicobacter Pylori Infection Treatment Revenue by Country (US$ Million) & (2027-2032) Table 95. Europe Helicobacter Pylori Infection Treatment Revenue by Type (2021-2026) & (US$ Million) Table 96. Europe Helicobacter Pylori Infection Treatment Revenue by Type (2027-2032) & (US$ Million) Table 97. Europe Helicobacter Pylori Infection Treatment Revenue by Application (2021-2026) & (US$ Million) Table 98. Europe Helicobacter Pylori Infection Treatment Revenue by Application (2027-2032) & (US$ Million) Table 99. Europe Helicobacter Pylori Infection Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. Europe Helicobacter Pylori Infection Treatment Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe Helicobacter Pylori Infection Treatment Revenue by Country (US$ Million) & (2027-2032) Table 102. China Helicobacter Pylori Infection Treatment Revenue by Type (2021-2026) & (US$ Million) Table 103. China Helicobacter Pylori Infection Treatment Revenue by Type (2027-2032) & (US$ Million) Table 104. China Helicobacter Pylori Infection Treatment Revenue by Application (2021-2026) & (US$ Million) Table 105. China Helicobacter Pylori Infection Treatment Revenue by Application (2027-2032) & (US$ Million) Table 106. Asia Helicobacter Pylori Infection Treatment Revenue by Type (2021-2026) & (US$ Million) Table 107. Asia Helicobacter Pylori Infection Treatment Revenue by Type (2027-2032) & (US$ Million) Table 108. Asia Helicobacter Pylori Infection Treatment Revenue by Application (2021-2026) & (US$ Million) Table 109. Asia Helicobacter Pylori Infection Treatment Revenue by Application (2027-2032) & (US$ Million) Table 110. Asia Helicobacter Pylori Infection Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 111. Asia Helicobacter Pylori Infection Treatment Revenue by Region (US$ Million) & (2021-2026) Table 112. Asia Helicobacter Pylori Infection Treatment Revenue by Region (US$ Million) & (2027-2032) Table 113. SAMEA Helicobacter Pylori Infection Treatment Revenue by Type (2021-2026) & (US$ Million) Table 114. SAMEA Helicobacter Pylori Infection Treatment Revenue by Type (2027-2032) & (US$ Million) Table 115. SAMEA Helicobacter Pylori Infection Treatment Revenue by Application (2021-2026) & (US$ Million) Table 116. SAMEA Helicobacter Pylori Infection Treatment Revenue by Application (2027-2032) & (US$ Million) Table 117. SAMEA Helicobacter Pylori Infection Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. SAMEA Helicobacter Pylori Infection Treatment Revenue by Country (2021-2026) & (US$ Million) Table 119. SAMEA Helicobacter Pylori Infection Treatment Revenue by Country (US$ Million) & (2027-2032) Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Helicobacter Pylori Infection Treatment Image Figure 2. Global Helicobacter Pylori Infection Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Helicobacter Pylori Infection Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Bismuth-quadruple Therapy Image Figure 5. Concomitant Therapy Image Figure 6. Levofloxacin Triple Therapy Image Figure 7. Bismuth Therapy Image Figure 8. High-dose Dual Therapy Image Figure 9. Global Helicobacter Pylori Infection Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Helicobacter Pylori Infection Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospitals Image Figure 12. Diagnostics Laboratories Image Figure 13. Clinics Image Figure 14. Global Helicobacter Pylori Infection Treatment Market Size (US$ Million) & (2021-2032) Figure 15. Global Helicobacter Pylori Infection Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Helicobacter Pylori Infection Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Helicobacter Pylori Infection Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Helicobacter Pylori Infection Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Helicobacter Pylori Infection Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Helicobacter Pylori Infection Treatment Revenue Market Share by Type (2021-2032) Figure 22. Global Helicobacter Pylori Infection Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Helicobacter Pylori Infection Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Helicobacter Pylori Infection Treatment Revenue Market Share by Application (2021-2032) Figure 25. North America Helicobacter Pylori Infection Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Helicobacter Pylori Infection Treatment Revenue Share by Type (2021-2032) Figure 27. North America Helicobacter Pylori Infection Treatment Revenue Share by Application (2021-2032) Figure 28. North America Helicobacter Pylori Infection Treatment Revenue Share by Country (2021-2032) Figure 29. United States Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Helicobacter Pylori Infection Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Helicobacter Pylori Infection Treatment Revenue Share by Type (2021-2032) Figure 34. Europe Helicobacter Pylori Infection Treatment Revenue Share by Application (2021-2032) Figure 35. Europe Helicobacter Pylori Infection Treatment Revenue Share by Country (2021-2032) Figure 36. Germany Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Helicobacter Pylori Infection Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Helicobacter Pylori Infection Treatment Revenue Share by Type (2021-2032) Figure 46. China Helicobacter Pylori Infection Treatment Revenue Share by Application (2021-2032) Figure 47. Asia Helicobacter Pylori Infection Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Helicobacter Pylori Infection Treatment Revenue Share by Type (2021-2032) Figure 49. Asia Helicobacter Pylori Infection Treatment Revenue Share by Application (2021-2032) Figure 50. Asia Helicobacter Pylori Infection Treatment Revenue Share by Region (2021-2032) Figure 51. Japan Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Helicobacter Pylori Infection Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Helicobacter Pylori Infection Treatment Revenue Share by Type (2021-2032) Figure 59. SAMEA Helicobacter Pylori Infection Treatment Revenue Share by Application (2021-2032) Figure 60. SAMEA Helicobacter Pylori Infection Treatment Revenue Share by Country (2021-2032) Figure 61. Brazil Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Helicobacter Pylori Infection Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Bismuth-quadruple Therapy
  • Concomitant Therapy
  • Levofloxacin Triple Therapy
  • Bismuth Therapy
  • High-dose Dual Therapy
Applications
  • Hospitals
  • Diagnostics Laboratories
  • Clinics
Companies covered
  • Cumberland Pharmaceuticals
  • Eisai Co.
  • Bio-Rad Laboratories
  • F. Hoffmann-La Roche
  • Alpha Laboratories
  • Biohit
  • Phathom Pharmaceuticals
  • Redhill Biopharma
  • Takeda Pharmaceuticals
  • AbbVie

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Helicobacter Pylori Infection Treatment Market by Type
  3. 1.2.1 Global Helicobacter Pylori Infection Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Bismuth-quadruple Therapy
  5. 1.2.3 Concomitant Therapy
  6. 1.2.4 Levofloxacin Triple Therapy
  7. 1.2.5 Bismuth Therapy
  8. 1.2.6 High-dose Dual Therapy
  9. 1.3 Helicobacter Pylori Infection Treatment Market by Application
  10. 1.3.1 Global Helicobacter Pylori Infection Treatment Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospitals
  12. 1.3.3 Diagnostics Laboratories
  13. 1.3.4 Clinics
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Helicobacter Pylori Infection Treatment Market Dynamics
  1. 2.1 Helicobacter Pylori Infection Treatment Industry Trends
  2. 2.2 Helicobacter Pylori Infection Treatment Industry Drivers
  3. 2.3 Helicobacter Pylori Infection Treatment Industry Opportunities and Challenges
  4. 2.4 Helicobacter Pylori Infection Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Helicobacter Pylori Infection Treatment Market Perspective (2021-2032)
  2. 3.2 Global Helicobacter Pylori Infection Treatment Growth Trends by Region
  3. 3.2.1 Global Helicobacter Pylori Infection Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Helicobacter Pylori Infection Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Helicobacter Pylori Infection Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Helicobacter Pylori Infection Treatment Revenue by Players
  2. 4.1.1 Global Helicobacter Pylori Infection Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Helicobacter Pylori Infection Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Helicobacter Pylori Infection Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Helicobacter Pylori Infection Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Helicobacter Pylori Infection Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Helicobacter Pylori Infection Treatment Players, Product Type & Application
  8. 4.5 Global Helicobacter Pylori Infection Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Helicobacter Pylori Infection Treatment Market CR5 and HHI
  11. 4.6.3 2025 Helicobacter Pylori Infection Treatment Tier 1, Tier 2, and Tier 3
5 Helicobacter Pylori Infection Treatment Market Size by Type
  1. 5.1 Global Helicobacter Pylori Infection Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Helicobacter Pylori Infection Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Helicobacter Pylori Infection Treatment Revenue Market Share by Type (2021-2032)
6 Helicobacter Pylori Infection Treatment Market Size by Application
  1. 6.1 Global Helicobacter Pylori Infection Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Helicobacter Pylori Infection Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Helicobacter Pylori Infection Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Cumberland Pharmaceuticals
  2. 7.1.1 Cumberland Pharmaceuticals Company Information
  3. 7.1.2 Cumberland Pharmaceuticals Business Overview
  4. 7.1.3 Cumberland Pharmaceuticals Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Cumberland Pharmaceuticals Helicobacter Pylori Infection Treatment Product Portfolio
  6. 7.1.5 Cumberland Pharmaceuticals Recent Developments
  7. 7.2 Eisai Co.
  8. 7.2.1 Eisai Co. Company Information
  9. 7.2.2 Eisai Co. Business Overview
  10. 7.2.3 Eisai Co. Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Eisai Co. Helicobacter Pylori Infection Treatment Product Portfolio
  12. 7.2.5 Eisai Co. Recent Developments
  13. 7.3 Bio-Rad Laboratories
  14. 7.3.1 Bio-Rad Laboratories Company Information
  15. 7.3.2 Bio-Rad Laboratories Business Overview
  16. 7.3.3 Bio-Rad Laboratories Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bio-Rad Laboratories Helicobacter Pylori Infection Treatment Product Portfolio
  18. 7.3.5 Bio-Rad Laboratories Recent Developments
  19. 7.4 F. Hoffmann-La Roche
  20. 7.4.1 F. Hoffmann-La Roche Company Information
  21. 7.4.2 F. Hoffmann-La Roche Business Overview
  22. 7.4.3 F. Hoffmann-La Roche Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 F. Hoffmann-La Roche Helicobacter Pylori Infection Treatment Product Portfolio
  24. 7.4.5 F. Hoffmann-La Roche Recent Developments
  25. 7.5 Alpha Laboratories
  26. 7.5.1 Alpha Laboratories Company Information
  27. 7.5.2 Alpha Laboratories Business Overview
  28. 7.5.3 Alpha Laboratories Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Alpha Laboratories Helicobacter Pylori Infection Treatment Product Portfolio
  30. 7.5.5 Alpha Laboratories Recent Developments
  31. 7.6 Biohit
  32. 7.6.1 Biohit Company Information
  33. 7.6.2 Biohit Business Overview
  34. 7.6.3 Biohit Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Biohit Helicobacter Pylori Infection Treatment Product Portfolio
  36. 7.6.5 Biohit Recent Developments
  37. 7.7 Phathom Pharmaceuticals
  38. 7.7.1 Phathom Pharmaceuticals Company Information
  39. 7.7.2 Phathom Pharmaceuticals Business Overview
  40. 7.7.3 Phathom Pharmaceuticals Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Phathom Pharmaceuticals Helicobacter Pylori Infection Treatment Product Portfolio
  42. 7.7.5 Phathom Pharmaceuticals Recent Developments
  43. 7.8 Redhill Biopharma
  44. 7.8.1 Redhill Biopharma Company Information
  45. 7.8.2 Redhill Biopharma Business Overview
  46. 7.8.3 Redhill Biopharma Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Redhill Biopharma Helicobacter Pylori Infection Treatment Product Portfolio
  48. 7.8.5 Redhill Biopharma Recent Developments
  49. 7.9 Takeda Pharmaceuticals
  50. 7.9.1 Takeda Pharmaceuticals Company Information
  51. 7.9.2 Takeda Pharmaceuticals Business Overview
  52. 7.9.3 Takeda Pharmaceuticals Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Takeda Pharmaceuticals Helicobacter Pylori Infection Treatment Product Portfolio
  54. 7.9.5 Takeda Pharmaceuticals Recent Developments
  55. 7.10 AbbVie
  56. 7.10.1 AbbVie Company Information
  57. 7.10.2 AbbVie Business Overview
  58. 7.10.3 AbbVie Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 AbbVie Helicobacter Pylori Infection Treatment Product Portfolio
  60. 7.10.5 AbbVie Recent Developments
8 North America
  1. 8.1 North America Helicobacter Pylori Infection Treatment Revenue (2021-2032)
  2. 8.2 North America Helicobacter Pylori Infection Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Helicobacter Pylori Infection Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Helicobacter Pylori Infection Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Helicobacter Pylori Infection Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Helicobacter Pylori Infection Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Helicobacter Pylori Infection Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Helicobacter Pylori Infection Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Helicobacter Pylori Infection Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Helicobacter Pylori Infection Treatment Revenue by Country
  11. 8.6.1 North America Helicobacter Pylori Infection Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Helicobacter Pylori Infection Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Helicobacter Pylori Infection Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Helicobacter Pylori Infection Treatment Revenue (2021-2032)
  2. 9.2 Europe Helicobacter Pylori Infection Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Helicobacter Pylori Infection Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Helicobacter Pylori Infection Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Helicobacter Pylori Infection Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Helicobacter Pylori Infection Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Helicobacter Pylori Infection Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Helicobacter Pylori Infection Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Helicobacter Pylori Infection Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Helicobacter Pylori Infection Treatment Revenue by Country
  11. 9.6.1 Europe Helicobacter Pylori Infection Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Helicobacter Pylori Infection Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Helicobacter Pylori Infection Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Helicobacter Pylori Infection Treatment Revenue (2021-2032)
  2. 10.2 China Helicobacter Pylori Infection Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Helicobacter Pylori Infection Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Helicobacter Pylori Infection Treatment Revenue by Type (2027-2032)
  5. 10.3 China Helicobacter Pylori Infection Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Helicobacter Pylori Infection Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Helicobacter Pylori Infection Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Helicobacter Pylori Infection Treatment Revenue by Application (2027-2032)
  9. 10.5 China Helicobacter Pylori Infection Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Helicobacter Pylori Infection Treatment Revenue (2021-2032)
  2. 11.2 Asia Helicobacter Pylori Infection Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Helicobacter Pylori Infection Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Helicobacter Pylori Infection Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Helicobacter Pylori Infection Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Helicobacter Pylori Infection Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Helicobacter Pylori Infection Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Helicobacter Pylori Infection Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Helicobacter Pylori Infection Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Helicobacter Pylori Infection Treatment Revenue by Country
  11. 11.6.1 Asia Helicobacter Pylori Infection Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Helicobacter Pylori Infection Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Helicobacter Pylori Infection Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Helicobacter Pylori Infection Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Helicobacter Pylori Infection Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Helicobacter Pylori Infection Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Helicobacter Pylori Infection Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Helicobacter Pylori Infection Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Helicobacter Pylori Infection Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Helicobacter Pylori Infection Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Helicobacter Pylori Infection Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Helicobacter Pylori Infection Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Helicobacter Pylori Infection Treatment Revenue by Country
  11. 12.6.1 SAMEA Helicobacter Pylori Infection Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Helicobacter Pylori Infection Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Helicobacter Pylori Infection Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst